JAK inhibitor Upadacitinib, Purity ≥98%

Synonym: Upadacitinib; 1310726-60-3; ABT-494; Rinvoq; Upadacitinib anhydrous; 4RA0KN46E0; UNII-4RA0KN46E0; JAK inhibitor

MDL: MFCD30502663
CAS Number: 1310726-60-3
Compound CID: 58557659

Product Size

2 mg; 5 mg; 10 mg; 25 mg; 50 mg

Price

Datasheet

MSDS

Properties

Description

Upadacitinib, soluble in DMSO and ethanol and insoluble in water, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.

Molecular Weight

380.37

Molecular Formula

C₁₇H₁₉F₃N₆O

Targets

JAK1: 0.043 μM; JAK2: 0.2 μM; JAK3: 2.3 μM; Tyk2: 4.7 μM

Form

Lyophilized powder

Purity

Solubility

DMSO: 66 mg/mL (173.51 mM); Water: Insoluble; Ethanol: 66 mg/mL (173.51 mM)

Identity

Confirmed by NMR/HPLC/MS.

Applications

Upadacitinib can be used in research targeting JAK1 for treating autoimmune diseases.